{"id":"https://openalex.org/W2249288343","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4007","title":"Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab","display_name":"Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2249288343","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4007","mag":"2249288343"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.4007","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4007","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4007","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113711211","display_name":"J. C. Yao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. C. Yao","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053460346","display_name":"Chaan S. Ng","orcid":"https://orcid.org/0000-0001-9261-7021","observed_orcids":["https://orcid.org/0000-0001-9261-7021"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Ng","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103595505","display_name":"P. M. Hoff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. M. Hoff","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. T. Phan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. T. Phan","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014750199","display_name":"Ken Hess","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Hess","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":null,"display_name":"H. Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Chen","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102021659","display_name":"X. Wang","orcid":"https://orcid.org/0000-0003-2660-0859","observed_orcids":["https://orcid.org/0000-0003-2660-0859"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"X. Wang","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110481222","display_name":"James L. Abbruzzese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. L. Abbruzzese","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044064524","display_name":"Jaffer A. Ajani","orcid":"https://orcid.org/0000-0001-9946-0629","observed_orcids":["https://orcid.org/0000-0001-9946-0629"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. A. Ajani","raw_affiliation_strings":["UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":56,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"4007","last_page":"4007"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9204000234603882,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9204000234603882,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0406000018119812,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.015399999916553497,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carcinoid-tumor","display_name":"carcinoid tumor","score":0.7519999742507935},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9750000238418579},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.9480000138282776},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6930000185966492},{"id":"https://openalex.org/keywords/tumor-perfusion","display_name":"tumor perfusion","score":0.9860000014305115},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.8109999895095825},{"id":"https://openalex.org/keywords/functional-ct","display_name":"functional CT","score":0.6190000176429749},{"id":"https://openalex.org/keywords/5-hydroxyindoleacetic-acid","display_name":"5-hydroxyindoleacetic acid","score":0.7960000038146973},{"id":"https://openalex.org/keywords/octreotide","display_name":"octreotide","score":0.9629999995231628},{"id":"https://openalex.org/keywords/metastatic-neuroendocrine-tumors","display_name":"metastatic neuroendocrine tumors","score":0.8920000195503235},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6330000162124634}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9478722214698792},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8900509476661682},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.6319891810417175},{"id":"https://openalex.org/C146957229","wikidata":"https://www.wikidata.org/wiki/Q1266915","display_name":"Perfusion","level":2,"score":0.5270626544952393},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5020201206207275},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4722282886505127},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.44607263803482056},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3297075927257538}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.4007","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4007","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4007","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2597939001","https://openalex.org/W2166100060","https://openalex.org/W1981791928","https://openalex.org/W1970248216","https://openalex.org/W2093882050","https://openalex.org/W2231519804","https://openalex.org/W17551312","https://openalex.org/W1974956292","https://openalex.org/W2589545206","https://openalex.org/W2256851415"],"abstract_inverted_index":{"4007":[0],"Background:":[1],"Carcinoid":[2],"is":[3,16,109,283],"a":[4,24,47],"vascular":[5],"tumor":[6,146,170,288],"that":[7],"expresses":[8],"VEGF.":[9],"Effective":[10],"systemic":[11],"therapy":[12,22,56,282],"for":[13,61],"advanced":[14],"disease":[15],"lacking.":[17],"We":[18,140,163],"are":[19],"evaluating":[20],"anti-angiogenic":[21],"in":[23,36,79,145,169,230,244,248,260,264,278,296,308],"phase":[25],"II":[26],"study":[27],"of":[28,50,106,122,134,151,181,240,255,287,293,300],"Bevacizumab":[29],"(BVZ)":[30],"and":[31,86,268,291],"PEG":[32],"Interferon":[33],"alpha-2b":[34],"(PEGI)":[35],"patients":[37,68,108,129,222,309],"with":[38,57,153,285],"metastatic":[39],"or":[40,59,138,316,319],"unresectable":[41],"carcinoid":[42,297],"tumors.":[43,298],"Methods:":[44],"Patients":[45],"on":[46,212,218,224,266,270],"stable":[48],"dose":[49,180],"octreotide":[51,135],"were":[52,97,242],"randomly":[53],"assigned":[54],"to":[55,76,304,311],"BVZ":[58,137,154,213,232,245,267,281],"PEGI":[60,215,219,249,301],"18":[62,65,132,174,238,253],"weeks.":[63],"After":[64],"weeks,":[66],"the":[67,178,231,252],"receive":[69],"both":[70],"drugs.":[71],"Functional":[72],"CT":[73,157],"was":[74,228,262],"used":[75],"monitor":[77],"changes":[78],"blood":[80,83,289],"flow":[81,290],"(BF),":[82],"volume":[84],"(BV),":[85],"permeability":[87],"surface":[88],"(PS).":[89],"PFS":[90,226,235,294],"durations,":[91],"calculated":[92],"by":[93,99,155],"Kaplan":[94],"Meier":[95],"method,":[96],"compared":[98],"log":[100],"rank":[101],"test.":[102],"Results:":[103],"Planned":[104],"accrual":[105],"44":[107],"complete.":[110],"41":[111],"(20":[112],"BVZ,":[113,126,189,195,201],"21":[114],"PEGI)":[115,128,203],"have":[116,130,141,204],"completed":[117,131],"at":[118,172],"least":[119],"9":[120],"weeks":[121,133,239,254],"therapy.":[123],"35":[124],"(18":[125],"17":[127],"plus":[136],"PEGI.":[139,271],"previously":[142],"reported":[143,166],"decreased":[144],"perfusion":[147,171],"within":[148],"48":[149],"hours":[150],"treatment":[152],"functional":[156],"(ASCO":[158],"2004":[159],"abstr":[160],"#":[161],"3013).":[162],"now":[164],"also":[165],"sustained":[167],"decrease":[168],"week":[173],"(21":[175],"days":[176],"after":[177,237],"previous":[179],"bevacizumab).":[182],"By":[183],"RECIST":[184],"criteria,":[185],"3":[186],"PR":[187,211],"(3":[188],"0":[190],"PEGI),":[191,197],"31":[192],"SD":[193],"(16":[194],"15":[196],"6":[198],"PD":[199,217],"(1":[200],"5":[202],"been":[205],"observed.":[206],"An":[207],"additional":[208],"patient":[209],"achieved":[210,274],"+":[214],"following":[216],"alone.":[220],"Twenty-two":[221],"remain":[223],"study.":[225],"duration":[227,295],"superior":[229],"arm":[233],"(P=.01).":[234],"rates":[236],"monotherapy":[241],"95%":[243],"versus":[246],"67%":[247],"arm.":[250],"During":[251],"monotherapy,":[256],"\u2265":[257,275],"50%":[258,276],"reduction":[259,277],"5HIAA":[261],"observed":[263],"21%":[265],"43%":[269],"Overall,":[272],"46%":[273],"5HIAA.":[279],"Conclusions:":[280],"associated":[284],"suppression":[286],"prolongation":[292],"Addition":[299],"may":[302],"help":[303],"control":[305],"hormonal":[306],"output":[307],"refractory":[310],"octreotide.":[312],"Author":[313],"Disclosure":[314],"Employment":[315],"Leadership":[317],"Consultant":[318],"Advisory":[320],"Role":[321],"Stock":[322],"Ownership":[323],"Honoraria":[324],"Research":[325],"Funding":[326],"Expert":[327],"Testimony":[328],"Other":[329],"Remuneration":[330],"Genentech":[331]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}